CLINICAL TRIALS

Multiple Myeloma Clinical Trials in Arizona

10+ recruiting Multiple Myeloma trials in Arizona, simplified into plain English.

Informational only. Not medical advice. Always consult a qualified healthcare professional.
Data sourced from ClinicalTrials.gov (NLM/NIH).

ACTIVE NOT RECRUITINGPhase 1

Study of HPN217 in Participants With Relapsed/Refractory Multiple Myeloma MK-4002 (MK-4002-001)

Researchers want to learn if MK-4002 (also known as HPN217) can treat relapsed or refractory multiple myeloma (RRMM). The goals of this study are to learn about the safety of different doses of MK-4002 and how well peopl

NCT04184050 · Gilbert
ACTIVE NOT RECRUITINGPhase 3

Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma

This study will evaluate the efficacy and safety of belantamab mafodotin in combination with pomalidomide and dexamethasone (Arm A) compared with that of combination of pomalidomide, bortezomib and dexamethasone (Arm B)

NCT04484623 · Tucson
RECRUITINGPhase 2

A Study to Investigate Subcutaneous Isatuximab in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma

The primary purpose of this study is to assess the efficacy (overall response rate) of subcutaneous (SC) via on body delivery system (SC-OBDS) isatuximab in combination with weekly carfilzomib and dexamethasone (Kd) in a

NCT06356571 · Phoenix
RECRUITING

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

This study is an access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs) in pediatric and adult patients with hematologic malignancies and other indications.

NCT01351545 · Gilbert
ACTIVE NOT RECRUITINGPhase 3

A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis (CARES)

AL (or light chain) amyloidosis begins in the bone marrow where abnormal proteins misfold and create free light chains that cannot be broken down. These free light chains bind together to form amyloid fibrils that build

NCT04512235 · Scottsdale
ACTIVE NOT RECRUITINGPhase 1

P-BCMA-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Multiple Myeloma

Phase 1 study comprised of open-label, dose escalation, multiple cohorts of P-BCMA-ALLO1 allogeneic T stem cell memory (Tscm) CAR-T cells in subjects with relapsed / refractory Multiple Myeloma (RRMM).

NCT04960579 · Goodyear
ACTIVE NOT RECRUITINGPhase 3

SC Versus IV Isatuximab in Combination With Pomalidomide and Dexamethasone in RRMM

This is a randomized, multicenter, Phase 3, open-label study evaluating subcutaneous (SC) vs intravenous (IV) administration of isatuximab in combination with pomalidomide and dexamethasone (Pd) in RRMM patients (study p

NCT05405166 · Bullhead City
RECRUITINGPhase 4

A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel

The purpose of this study is to collect long-term follow-up data on delayed adverse events after administration of ciltacabtagene autoleucel (cilta-cel), and to characterize and understand the long-term safety profile of

NCT05201781 · Phoenix
ACTIVE NOT RECRUITINGPhase 1

Study of Oral LOXO-338 in Patients With Advanced Blood Cancers

The purpose of this study is to find out whether the study drug, LOXO-338, is safe and effective in patients with advanced blood cancer. Patients must have already received standard therapy. The study may last up to appr

NCT05024045 · Tucson
ACTIVE NOT RECRUITINGPhase 1

A Study of Belantamab Mafodotin Monotherapy in Multiple Myeloma Participants With Normal and Varying Degree of Impaired Renal Function

Belantamab mafodotin is an antibody-drug conjugate (ADC) containing humanized anti- B-cell maturation antigen (BCMA) monoclonal antibody (mAb). Renal impairment is a major complication of multiple myeloma (MM) and the ma

NCT04398745 · Tucson

RECOMMENDED RESOURCES FOR MULTIPLE MYELOMA

🛡️

GoHealth

Medicare Specialist

Compare Medicare Advantage and Supplement plans with a licensed advisor. Many patients with chronic conditions qualify for $0-premium plans with extra benefits.

Check Your Coverage →

Clinicals AI may earn a referral fee. At no cost to you.

COMMON QUESTIONS

Are there Multiple Myeloma clinical trials in Arizona?

Yes. Clinicals AI lists 10+ recruiting Multiple Myeloma trials in Arizona sourced from ClinicalTrials.gov. Browse them above or search across all states.

How do I qualify for a Multiple Myeloma trial in Arizona?

Eligibility varies by study. Most trials require a confirmed Multiple Myeloma diagnosis, fall within a specific age range, and may have restrictions based on prior treatments. Review each listing's criteria and submit a contact request for more details.

Are Multiple Myeloma clinical trials free to join?

Most trials cover the investigational treatment and all study-related visits. Some also offer compensation for travel and time. Always confirm the cost structure with the trial coordinator before enrolling.